WEKO3
アイテム
A Phase I/II Trial of Definitive Carbon Ion Radiotherapy for Clinical T1bN0M0 Esophageal Squamous Cell Carcinoma.
https://repo.qst.go.jp/records/2000770
https://repo.qst.go.jp/records/2000770e5757eb0-03e8-4de5-8984-54212f3b9600
| アイテムタイプ | 学術雑誌論文 / Journal Article(1) | |||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2024-12-19 | |||||||||||||||||||||||||||||||||||
| タイトル | ||||||||||||||||||||||||||||||||||||
| タイトル | A Phase I/II Trial of Definitive Carbon Ion Radiotherapy for Clinical T1bN0M0 Esophageal Squamous Cell Carcinoma. | |||||||||||||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||||||||||||||
| 言語 | ||||||||||||||||||||||||||||||||||||
| 言語 | eng | |||||||||||||||||||||||||||||||||||
| 資源タイプ | ||||||||||||||||||||||||||||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||||||||||||||||||||||||||||
| 資源タイプ | journal article | |||||||||||||||||||||||||||||||||||
| 著者 |
Tetsuro Isozaki
× Tetsuro Isozaki
× Hitoshi Ishikawa
× Shigeo Yasuda
× Yuka Isozaki
× Shigeru Yamada
× Yasunori Akutsu
× Matsuo Nagata
× Yoshihiro Nabeya
× Keiko Minashi
× Kentaro Murakami
× Hiroyuki Kuwano
× Kenji Nemoto
× Hiroshi Tsuji
× Takashi Uno
× Hisahiro Matsubara
|
|||||||||||||||||||||||||||||||||||
| 抄録 | ||||||||||||||||||||||||||||||||||||
| 内容記述タイプ | Abstract | |||||||||||||||||||||||||||||||||||
| 内容記述 | Japanese guidelines recommend surgery or chemoradiotherapy (CRT) for submucosal (T1b) esophageal cancer. Approximately 44.5% of all patients with esophageal cancer are aged ?70 years,1 and hence, surgery and chemotherapy may be unsuitable owing to comorbidities associated with old age. Therefore, less-invasive and effective treatments are needed for the management of esophageal cancer, especially in elderly patients. Recently, carbon ion radiation therapy (CIRT), which has several physical and biologic advantages over conventional radiation therapy (RT), has been developed as a cancer treatment.2,3 In the first clinical trial of CIRT for esophageal cancer, neoadjuvant CIRT without chemotherapy was tested as a dose-escalation study, and a complete response (CR) was pathologically achieved in nearly 100% of T1 cases.4 Therefore, we aimed to examine whether CIRT alone could cure clinical T1b esophageal carcinoma. However, the dose of CIRT that the normal esophagus can tolerate is still unknown. In this article, we report the first results of a phase 1/2 clinical trial of CIRT to evaluate the safety and effectiveness of clinical T1bN0M0 esophageal squamous cell carcinoma (ESCC). |
|||||||||||||||||||||||||||||||||||
| 書誌情報 |
International journal of radiation oncology, biology, physics 巻 117, 号 2, p. 416-421, 発行日 2023-04 |
|||||||||||||||||||||||||||||||||||
| 出版者 | ||||||||||||||||||||||||||||||||||||
| 出版者 | Elsevier, Inc | |||||||||||||||||||||||||||||||||||
| ISSN | ||||||||||||||||||||||||||||||||||||
| 収録物識別子タイプ | ISSN | |||||||||||||||||||||||||||||||||||
| 収録物識別子 | 1879-355X | |||||||||||||||||||||||||||||||||||
| PubMed番号 | ||||||||||||||||||||||||||||||||||||
| 識別子タイプ | PMID | |||||||||||||||||||||||||||||||||||
| 関連識別子 | 37116590 | |||||||||||||||||||||||||||||||||||
| DOI | ||||||||||||||||||||||||||||||||||||
| 識別子タイプ | DOI | |||||||||||||||||||||||||||||||||||
| 関連識別子 | 10.1016/j.ijrobp.2023.04.014 | |||||||||||||||||||||||||||||||||||
